Diaceutics CEO Ryan Keeling talks to solli about pharma's execution gap

Commercial Strategy Optimization HCP Engagement & Activation Pre-launch
Diaceutics Team
Diagnostic Driven Commercialization
Marketing
Connect

Diaceutics CEO, Ryan Keeling, features in solli's October series on HCP and patient engagement. In the article Pharma Faces an Execution Gap Between Diagnosis and Treatment. How Can Marketers Close It?, Andrea Park explores why so many eligible patients don't reach the right therapy, and what pharma marketers can do about it.

The feature draws on the Diaceutics Strategic Collaboration Survey 2026. We asked 125 biopharma professionals how well their organizations move patients from diagnosis to treatment. They see it as a commercial priority, giving it an average score of 7.5/10 as a driver of future success. But they rate their ability to act on it lower: 5.2/10 for turning diagnostic insight into coordinated action, and 5.4/10 for visibility across the patient journey.

 

Ryan told solli: "Pharma doesn't have a data shortage, it has an execution problem."

Andrea's article goes on to look at how media strategy, HCP targeting and measurement may need to change, and why collaboration across the industry will be key.

Where are patients getting lost in your brand's pathway?
Our team works with biopharma brands to find where eligible patients are being missed between diagnosis and treatment, and what can be done about it.
Contact us

FAQS

What is the execution gap in pharma?
It's the difference between recognizing a commercial priority and being able to act on it. In the Diaceutics Strategic Collaboration Survey 2026, biopharma professionals gave diagnosis-to-treatment conversion an average score of 7.5/10 as a driver of future commercial success. They rated their ability to turn diagnostic insight into coordinated action at 5.2/10.
Why does diagnosis-to-treatment conversion matter for pharma marketers?
Diagnostic-driven brands depend on eligible patients actually starting the right therapy, and patients can be missed at several points before that happens. In the Diaceutics Strategic Collaboration Survey 2026, 48.8% of biopharma professionals rated identified patients not starting the appropriate therapy as an 8-10 out of 10 challenge. Knowing where patients are missed shows marketers where their work can make a difference.
How can pharma marketers measure impact beyond reach?
By tracking whether their activity helps patients move along the pathway, from the first test to the start of treatment. The Strategic Collaboration roundtable recommended measuring conversion as well as activity, so teams can see whether identification and testing lead to an appropriate treatment decision.
What role does collaboration play in closing the execution gap?
Moving a patient from diagnosis to treatment involves commercial, medical, data and access teams, as well as partners across the ecosystem. In the Diaceutics Strategic Collaboration Survey 2026, 24.0% of biopharma professionals named team misalignment as a top barrier to eligible patients receiving the appropriate therapy. The Strategic Collaboration roundtable recommended coordinating activity around the patient journey, with clear ownership at each stage.
What data do pharma marketers need to act sooner?
Timely, connected signals that show where patients are in the pathway and where action is needed. In the Diaceutics Strategic Collaboration Survey 2026, biopharma professionals rated their visibility across the patient journey at an average of 5.4/10. The Strategic Collaboration roundtable recommended connecting data to decisions, so teams can see where to step in while it still makes a difference.
How can pharma marketers reach the right HCPs at the right time?
By engaging while the treatment decision is still open. Treatment-decision windows are getting shorter, so commercial and field teams need early signals about patient identification, testing, referral and treatment readiness. In the Diaceutics Strategic Collaboration Survey 2026, about 1 in 3 biopharma professionals (32.0%) reported high confidence in identifying eligible patients early enough to influence treatment decisions.
Written By Diaceutics Team
Perspectives from the Diaceutics Marketing team on how diagnostic-driven commercialization can help more eligible patients reach the right therapy.
Read more by this author
Commercial Strategy Optimization HCP Engagement & Activation Pre-launch
Share:

Newsletter sign up

Sign up to our bi-weekly newsletter covering the latest insights to optimize commercialization of diagnostic driven therapies to help empower your decisions.

READY TO DO COMMERCIALIZATION DIFFERENTLY?

Every patient journey contains opportunities to improve testing, engagement, and adoption. We can help you find them so more people get the right therapy sooner.